HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A2540 Anti-Complement C3 Anti-Complement C3 (NGM621) is an antibody targeting Complement C3. It binds with high affinity to intact human C3. It is used in the research for treatment of Geographic Atrophy. MW: 145.5 KD. Aug 10 2023
A2541 Anti-Clusterin Anti-Clusterin (AB-16B5) is a humanized IgG2 antibody targeted against clusterin. It is an inhibitor of the epithelial to mesenchymal transition. Anti-Clusterin (AB-16B5) can be used for cancer research. MW: 145.5 KD. Aug 10 2023
A2542 Tepoditamab (Anti-CLEC12A / CD371) Tepoditamab (Anti-CLEC12A / CD371) is a bispecific monoclonal antibody that targets and binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. MW: 145.5 KD. Aug 10 2023
A2543 Tinurilimab (Anti-CEACAM6 / CD66c) Tinurilimab (Anti-CEACAM6 / CD66c) is an monoclonal antibody targeting against CEACAM6 and CD66c. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. MW: 145.5 KD. Aug 10 2023
A2544 Tusamitamab (Anti-CEACAM5 / CEA / CD66e) Tusamitamab (Anti-CEACAM5 / CEA / CD66e) is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine, which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative). MW: 145.5 KD. Aug 10 2023
A2545 Anti-CEACAM1 / CD66a Anti-CEACAM1 / CD66a (CM-24) is a humanized monoclonal immunoglobulin G4 (IgG4) antibody targeting CEACAM1 and CD66a, with potential immunomodulating and antineoplastic activities. It blocks the binding of CEACAM1-expressing cancer cells to CEACAM1-expressing immune cells and abrogates CEACAM1-mediated immunosuppression. MW: 145.5 KD. Aug 10 2023
A2546 Actoxumab (Anti-Cdiff Toxin A) Actoxumab ( (Anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab targeting TcdB. MW: 145.5 KD. Aug 10 2023
A2547 Anti-CDH6 / K-Cadherin Anti-CDH6 / K-Cadherin (DS-6000a) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting against the tumor-associated antigen cadherin-6. MW: 145.5 KD. Aug 10 2023
A2548 Anti-CDH3 / P-cadherin Anti-CDH3 / P-cadherin (PF-03732010) is a antibody targeting p-cadherin. It binds to and inhibits the activity of p-cadherin which may inhibit tumor cell invasion and proliferation in p-cadherin expressing tumor cells. MW: 145.5 KD. Aug 10 2023
A2549 Anti-CD98 Anti-CD98 (KHK2898) is an antibody targeting CD98. MW: 145.5 KD. Aug 10 2023
A2550 Polatuzumab (Anti-CD79b) Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD. Aug 10 2023
A2551 Milatuzumab (Anti-CD74) Milatuzumab (Anti-CD74) is a humanized monoclonal antibody targeting CD74, a integral membrane protein. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. MW:145.5 KD. Aug 10 2023
A2552 Itolizumab (Anti-CD6) Itolizumab (Anti-CD6) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis, COVID-19. MW:145.5 KD. Aug 10 2023
A2553 Alemtuzumab (Anti-CD52) Alemtuzumab (Anti-CD52) is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD. Aug 10 2023
A2554 Anti-CD46 Anti-CD46 (FOR46) is a human monoclonal antibody targeting against CD46. It specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. MW:145.5 KD. Aug 10 2023
A2555 Bivatuzumab (Anti-CD44v6) Bivatuzumab (Anti-CD44v6) is a humanized monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD. Aug 10 2023
A2300 Anti-VEGFR3 / FLT4 Anti-VEGFR3 / FLT4 is a fully-human monoclonal antibody directed against (VEGFR-3; Flt-4) with antiangiogenic activity.Anti-VEGFR3 / FLT4 also plays a critical role in the embryonic vascular system development. Aug 10 2023
A2556 Ibalizumab (Anti-CD4) Ibalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD. Aug 10 2023
A2301 Icrucumab (Anti-VEGFR1 / FLT1) Icrucumab (Anti-VEGFR1 / FLT1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody, with potential anti-tumor and anti-metastatic agent. It also act as a therapeutic anti-angiogenic agent in different pathological contexts. Aug 10 2023
A2557 Teplizumab (Anti-CD3e) Teplizumab (Anti-CD3e) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes. MW:145.5 KD. Aug 10 2023